SEC Comment Letter for ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895) (RCKT) — Jun 21, 2019
ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)
Date: June 21, 2019 · CIK: 0001281895 · Accession: 0000000000-19-010137
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232168
Letter
June 20, 2019 Gaurav Shah Chief Executive Officer Rocket Pharmaceuticals, Inc. The Empire State Building 350 Fifth Ave, Suite 7530 New York, NY 10118 Re:Rocket Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 17, 2019 File No. 333-232168 Dear Dr. Shah: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Donald Field at 202-551-3680 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
June 20, 2019
Gaurav Shah
Chief Executive Officer
Rocket Pharmaceuticals, Inc.
The Empire State Building
350 Fifth Ave, Suite 7530
New York, NY 10118
Re:Rocket Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 17, 2019
File No. 333-232168
Dear Dr. Shah:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Donald Field at 202-551-3680 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance